Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer

This trial will investigate a novel 3-fraction radiation regimen for participants undergoing breast-conserving therapy (BCT) for early breast cancer that will: 1) significantly reduce the duration of treatment and can be completed in one-week (5 working days) and 2) MRI-guided radiotherapy (MRIdian) would limit the volume of normal tissue radiated and therefore resultant toxicity. The hypothesis is that 3-fraction radiation therapy can be delivered safely without compromising the therapeutic ratio. Participants can expect to be on study for follow up up to 5 years.

Trial Details

NCT ID
NCT03936478
Phase
PHASE2
Sponsor
University of Wisconsin, Madison
Status
RECRUITING
Cancer Type
Lobular Carcinoma Breast Cancer
Interventions
  • MRIdian Radiation Treatment Unit
Locations (sample)
  • Madison, Wisconsin, United States|43.07305,-89.40123

Key Eligibility Criteria

  • For all participants
  • Participants should have no contraindications to undergo MRI scan as part of radiotherapy planning and treatment.
  • Lumpectomy cavity must be clearly visible on CT and MRI scan at radiotherapy simulation.
  • Pregnancy test negative in women of child bearing potential (WOCBP).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lobular Carcinoma Breast Cancer Trials on Trialify →